SEC Form 4 · accession 0001610717-26-000358
10x Genomics, Inc. · TXG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John R Stuelpnagel
Director
Period of report
Aug 11, 2026
Accepted (ET)
Aug 13, 2026 · 4:11 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001770787
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common StockF1 | Aug 11, 2026 | S | 17,000 | $57.5812 | D | 351,436 | D | |
| Class A Common Stock | Aug 11, 2026 | S | 3,000 | $58.725 | D | 348,436 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed in multiple trades at prices ranging from $57.50 to $58.1525. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.